Glycorex Transplantation
Developer of antibody‑selective extracorporeal blood‑treatment technologies and affinity adsorption columns. Technologies are used clinically to remove blood‑group specific and other antibodies from blood or plasma to enable blood‑group incompatible organ transplants and to process donor plasma (including production of low‑titer universal plasma). Clinical use reported since 2001 with international deployment. R&D priorities include therapies targeting autoantibodies and methods for producing universal donor plasma. Headquarters in Lund, Sweden; publicly listed on a Nordic growth market.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Disposable affinity adsorption column for anti‑A/B antibody reduction
Single‑use sterile adsorption column designed to selectively reduce anti‑A and anti‑B antibody titers in donated plasma (and applicable to platelets/whole blood), while preserving non‑target antibodies and key plasma proteins, to support production of low‑titer universal blood components.
Disposable affinity adsorption column for anti‑A/B antibody reduction
Single‑use sterile adsorption column designed to selectively reduce anti‑A and anti‑B antibody titers in donated plasma (and applicable to platelets/whole blood), while preserving non‑target antibodies and key plasma proteins, to support production of low‑titer universal blood components.
Services
Provision and delivery of single‑use adsorption columns and related consumables for plasma processing and extracorporeal antibody removal; operational support for clinical deployment and use with standard apheresis/dialysis equipment.
Project‑based research collaborations with academic and clinical partners to develop new adsorption‑based indications, run in‑vitro and clinical evaluations, and present findings at scientific conferences.
Provision and delivery of single‑use adsorption columns and related consumables for plasma processing and extracorporeal antibody removal; operational support for clinical deployment and use with standard apheresis/dialysis equipment.
Project‑based research collaborations with academic and clinical partners to develop new adsorption‑based indications, run in‑vitro and clinical evaluations, and present findings at scientific conferences.
Expertise Areas
- Extracorporeal immunoadsorption and antibody removal
- Blood component modification and universal plasma production
- Clinical protocol development for blood‑group incompatible transplantation
- Affinity ligand chemistry using biologically active carbohydrates
Key Technologies
- Immunoadsorption affinity columns
- Glycan‑based affinity ligands
- Gravity‑driven plasma processing
- Single‑use sterile adsorption devices
News & Updates
Delivery of a column intended for production of low‑titer universal plasma to a European hospital as part of a project to support convalescent plasma initiatives; CE‑marking activities were ongoing at the time.
Announcement of the first use of an antibody‑selective adsorption column to enable an ABO‑incompatible transplantation in Argentina.
Reported first use of an antibody‑selective adsorption column to enable an ABO‑incompatible organ transplant in Morocco.
Series of distribution agreements announced for distribution of adsorption columns in several international markets (examples available in press releases).
Device technology used clinically since 2001 with reported use in thousands of blood‑group incompatible transplants (reported figures >6,000 overall and >4,500 kidney transplants) and clinical results presented in numerous peer‑reviewed publications and conference abstracts.
Delivery of a column intended for production of low‑titer universal plasma to a European hospital as part of a project to support convalescent plasma initiatives; CE‑marking activities were ongoing at the time.
Announcement of the first use of an antibody‑selective adsorption column to enable an ABO‑incompatible transplantation in Argentina.
Reported first use of an antibody‑selective adsorption column to enable an ABO‑incompatible organ transplant in Morocco.
Series of distribution agreements announced for distribution of adsorption columns in several international markets (examples available in press releases).
Device technology used clinically since 2001 with reported use in thousands of blood‑group incompatible transplants (reported figures >6,000 overall and >4,500 kidney transplants) and clinical results presented in numerous peer‑reviewed publications and conference abstracts.